We previously reported on Janssen’s complaint alleging that Amgen’s filing of an aBLA for ustekinumab, a biosimilar of STELARA, infringes Amgen patents, and about Janssen seeking a preliminary injunction to block Amgen from...more
In 2017, three indirect-purchaser antitrust class actions were filed against Johnson & Johnson and Janssen Biotech, Inc., alleging that they engaged in anticompetitive conduct relating to the sale and marketing of J&J’s...more
4/13/2023
/ Abuse of Dominance ,
Anti-Competitive ,
Antitrust Litigation ,
Antitrust Provisions ,
Attorney's Fees ,
Class Action ,
Discovery ,
Janssen Pharmaceuticals ,
Johnson & Johnson ,
Pfizer ,
Settlement